Esprinet 将来の成長

BIT:PRT - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4,491	34	47	61	3
12/31/2025	4,342	30	39	54	3
12/31/2024	4,154	24	29	46	3
9/30/2024	4,022	20	-35	-28	N/A
6/30/2024	3,929	18	65	73	N/A
3/31/2024	3,893	-15	203	214	N/A
12/31/2023	3,985	-12	155	168	N/A
9/30/2023	4,211	-1	192	207	N/A
6/30/2023	4,411	2	102	120	N/A
3/31/2023	4,563	43	-198	-185	N/A
12/31/2022	4,684	47	-264	-251	N/A
9/30/2022	4,698	39	-146	-136	N/A
6/30/2022	4,633	40	-117	-110	N/A
3/31/2022	4,664	44	51	42	N/A
12/31/2021	4,691	44	16	22	N/A
9/30/2021	4,743	43	-60	-52	N/A
6/30/2021	4,894	46	-92	-84	N/A
3/31/2021	4,744	38	118	142	N/A
12/31/2020	4,492	31	71	78	N/A
9/30/2020	4,293	31	190	197	N/A
6/30/2020	4,063	24	320	327	N/A
3/31/2020	3,984	24	168	173	N/A
12/31/2019	3,945	23	156	161	N/A
9/30/2019	3,872	15	43	45	N/A
6/30/2019	3,751	15	-54	-51	N/A
3/31/2019	3,665	14	-22	-18	N/A
12/31/2018	3,571	14	125	128	N/A
9/30/2018	3,399	25	25	28	N/A
6/30/2018	3,318	26	N/A	122	N/A
3/31/2018	3,253	27	N/A	-16	N/A
12/31/2017	3,217	26	N/A	26	N/A
9/30/2017	3,244	24	N/A	-28	N/A
6/30/2017	3,234	23	N/A	-32	N/A
3/31/2017	3,172	25	N/A	35	N/A
12/31/2016	3,042	27	N/A	34	N/A
9/30/2016	2,814	24	N/A	69	N/A
6/30/2016	2,703	27	N/A	52	N/A
3/31/2016	2,692	28	N/A	7	N/A
12/31/2015	2,694	30	N/A	74	N/A
9/30/2015	2,561	28	N/A	7	N/A
6/30/2015	2,495	27	N/A	-47	N/A
3/31/2015	2,396	25	N/A	-34	N/A
12/31/2014	2,291	27	N/A	4	N/A
9/30/2014	2,147	27	N/A	45	N/A
6/30/2014	2,076	26	N/A	75	N/A
3/31/2014	2,034	27	N/A	34	N/A
12/31/2013	2,003	23	N/A	88	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PRTの予測収益成長率 (年間22.1% ) は貯蓄率 ( 2.5% ) を上回っています。

収益対市場: PRTの収益 ( 22.1% ) はItalian市場 ( 7.4% ) よりも速いペースで成長すると予測されています。

高成長収益: PRTの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: PRTの収益 ( 4.6% ) Italian市場 ( 4% ) よりも速いペースで成長すると予測されています。

高い収益成長: PRTの収益 ( 4.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PRTの自己資本利益率は、3年後には低くなると予測されています ( 7.9 %)。

Esprinet 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 8.3% to €6.53

Consensus EPS estimates fall by 96%

Consensus EPS estimates fall by 32%

Price target decreased by 7.3% to €11.93

Consensus EPS estimates fall by 10%

Price target decreased to €13.65

Recent updates

Investor sentiment deteriorates as stock falls 18%

New major risk - Financial position

Third quarter 2024 earnings released: EPS: €0.07 (vs €0.04 in 3Q 2023)

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Why Esprinet's (BIT:PRT) Earnings Are Better Than They Seem

Investor sentiment improves as stock rises 19%

Price target increased by 8.3% to €6.53

Second quarter 2024 earnings released: EPS: €0.001 (vs €0.66 loss in 2Q 2023)

CEO & Executive Director exercised options to buy €82k worth of stock.

First quarter 2024 earnings released: EPS: €0.06 (vs €0.12 in 1Q 2023)

Here's Why Shareholders Should Examine Esprinet S.p.A.'s (BIT:PRT) CEO Compensation Package More Closely

Full year 2023 earnings released: €0.24 loss per share (vs €0.96 profit in FY 2022)

Now 20% overvalued after recent price rise

Esprinet S.p.A., Annual General Meeting, Apr 24, 2024

Consensus EPS estimates fall by 96%

Second quarter 2023 earnings released: €0.65 loss per share (vs €0.16 profit in 2Q 2022)

Investor sentiment deteriorates as stock falls 28%

Esprinet S.p.A. to Report First Half, 2023 Results on Sep 12, 2023

Returns On Capital At Esprinet (BIT:PRT) Have Hit The Brakes

Esprinet S.p.A. completed the acquisition of Sifar Group Srl.

Consensus EPS estimates fall by 32%

First quarter 2023 earnings released: EPS: €0.12 (vs €0.20 in 1Q 2022)

Price target decreased by 7.3% to €11.93

Returns On Capital At Esprinet (BIT:PRT) Have Stalled

Investor sentiment deteriorates as stock falls 15%

Does Esprinet (BIT:PRT) Deserve A Spot On Your Watchlist?

Upcoming dividend of €0.54 per share at 6.1% yield

Esprinet S.p.A.'s (BIT:PRT) Intrinsic Value Is Potentially 73% Above Its Share Price

Full year 2022 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall by 10%

Now 21% undervalued

What Is Esprinet S.p.A.'s (BIT:PRT) Share Price Doing?

Third quarter 2022 earnings released: EPS: €0.11 (vs €0.13 in 3Q 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: €0.11 (vs €0.13 in 3Q 2021)

Returns On Capital Are Showing Encouraging Signs At Esprinet (BIT:PRT)

Is It Time To Consider Buying Esprinet S.p.A. (BIT:PRT)?

Price target decreased to €13.65

Second quarter 2022 earnings released: EPS: €0.16 (vs €0.24 in 2Q 2021)

Price target decreased to €14.83

Here's Why We Think Esprinet (BIT:PRT) Might Deserve Your Attention Today

Esprinet Confirms Interest in Carrying Out Voluntary Takeover Bid Concerning All the Ordinary Shares of Cellularline

What Does Esprinet S.p.A.'s (BIT:PRT) Share Price Indicate?

Is Esprinet (BIT:PRT) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analyst expectations

High number of new directors

Upcoming dividend of €0.54 per share

Price target decreased to €16.40

Investor sentiment deteriorated over the past week

At €10.74, Is Esprinet S.p.A. (BIT:PRT) Worth Looking At Closely?

These 4 Measures Indicate That Esprinet (BIT:PRT) Is Using Debt Reasonably Well

Price target increased to €19.03

With EPS Growth And More, Esprinet (BIT:PRT) Is Interesting

Third quarter 2021 earnings released: EPS €0.13 (vs €0.18 in 3Q 2020)

Esprinet (BIT:PRT) Hasn't Managed To Accelerate Its Returns

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS €0.24 (vs €0.079 in 2Q 2020)

Esprinet (BIT:PRT) Has A Rock Solid Balance Sheet

Here's Why I Think Esprinet (BIT:PRT) Is An Interesting Stock

Should You Think About Buying Esprinet S.p.A. (BIT:PRT) Now?

Price target increased to €15.76

Esprinet S.p.A. (BIT:PRT) Shares Could Be 29% Above Their Intrinsic Value Estimate

First quarter 2021 earnings released: EPS €0.21 (vs €0.083 in 1Q 2020)

Upcoming dividend of €0.54 per share

Esprinet S.p.A. (BIT:PRT) commences an Equity Buyback Plan for 2,540,706 shares, representing 4.99% of its issued share capital, under the authorization approved on April 7, 2021.

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Esprinet (BIT:PRT) Passed With Ease

Does Esprinet (BIT:PRT) Have A Healthy Balance Sheet?